NCT00533754

Brief Summary

The aim of the study is to show a higher expression of the Y402H polymorphism in the complement factor H in patients with AMD compared to healthy individuals. Additionaly a correlation between a subsided infection with chlamydia and patients with AMD and a factor H polymorphism will be investigated. An interrelationship with the VEGF-plasma level shall give more hints into the pathomechanism of AMD.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jul 2006

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2006

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

September 20, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 21, 2007

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2007

Completed
Last Updated

September 21, 2007

Status Verified

September 1, 2007

First QC Date

September 20, 2007

Last Update Submit

September 20, 2007

Conditions

Age-Related Macular Degeneration

Keywords

age-related macular degeneration, genetics

Outcome Measures

Primary Outcomes (1)

  • higher expression of the Y402H polymorphism in the complement factor H in patients with AMD compared to healthy individuals

Secondary Outcomes (1)

  • a correlation between a subsided infection with chlamydia and patients with AMD and a factor H polymorphism will be investigated. An interrelationship with the VEGF-plasma level shall give more hints into the pathomechanism of AMD

Interventions

drawing bloodPROCEDURE

Eligibility Criteria

Age55 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • man and women over 18 years old
  • Filled out informed consentBereitschaft zur Teilnahme
  • Diagnosis of non-exudative/ exudative age related macular dgeneneration

You may not qualify if:

  • inherited retinal diseases
  • other aquired retinal/ macular
  • missing informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rudoulf foundation Clinic

Vienna, Vienna, 1030, Austria

Location

MeSH Terms

Conditions

Macular Degeneration

Condition Hierarchy (Ancestors)

Retinal DegenerationRetinal DiseasesEye Diseases

Study Officials

  • Susanne Binder, M.D.

    Rudoulf Foundation Clinic

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 20, 2007

First Posted

September 21, 2007

Study Start

July 1, 2006

Study Completion

November 1, 2007

Last Updated

September 21, 2007

Record last verified: 2007-09

Locations

AU(1)